Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
RESEARCH TOOLSreports
Bausch + Lomb Corporation (BLCO) Stock Price & Analysis
65 Followers
BLCO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.62 - $21.95
Previous Close$14.64
Volume259.42K
Average Volume (3M)465.00K
Market Cap
$5.03B
Enterprise Value$9.20B
Total Cash (Recent Filing)$355.00M
Total Debt (Recent Filing)$4.46B
Price to Earnings (P/E)-19.7
Beta0.73
Next Earnings
May 01, 2024EPS Estimate
$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding350,992,243
10 Day Avg. Volume740,324
30 Day Avg. Volume464,998
Standard Deviation0.08
R-Squared0.06
Alpha-0.00031
Financial Highlights & Ratios
Price to Book (P/B)-3.83
Price to Sales (P/S)5.24
Price to Cash Flow (P/CF)83.80
P/FCF Ratio41.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda25.14
Forecast
1Y Price Target
$19.57Price Target Upside33.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bausch + Lomb Corporation News
PremiumCompany Announcements
Bausch + Lomb’s Breakthrough in Dry Eye Relief
PremiumCompany Announcements
Bausch + Lomb Announces Q1 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial Outlook And PerformanceAnalysts are raising sales estimates for the company based on robust dry eye market trends, with expectations of continued revenue growth across its Vision Care, Surgical, and Pharmaceuticals segments.
Product Performance And Market ShareMiebo's impressive market share growth to 10% in just seven months since its launch demonstrates its strong performance and increasing acceptance among dry eye treatments.
Strategic Initiatives And Market ExpectationsThe company's strategic approach to cross-selling dry eye disease products, including Miebo and Xiidra, positions it to potentially revitalize Xiidra sales and achieve its ambitious $400 million revenue target.
Bears Say
Market ShareXiidra's Rx share fell from 24% to 19% in the past year.
Patent IssuesBased on consultant feedback, there is a belief that the company may ultimately lose the patent fight.
Product PerformanceXiidra monthly TRx fell significantly in the recent months.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $13.62 and its highest was $21.95 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Currently, no data Available
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Feb 21, 2024. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.169 by $0.071.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is $0.07.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 350,992,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.24 in its last earnings report, beating expectations of $0.169. Following the earnings report the stock price went up 13.777%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Among the largest hedge funds holding Bausch + Lomb Corporation’s share is Goldentree Asset Management Lp. It holds Bausch + Lomb Corporation’s shares valued at 80M.
---
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.57 (33.67% Upside)
$19.57 (33.67% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.04%
12-Months-Change
Fundamentals
Return on Equity
-3.75%
Trailing 12-Months
Asset Growth
20.62%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
---
BLCO Company Deck
---
BLCO Earnings Call
Q4 2024
0:00 / 0:00
---
BLCO Stock 12 Months Forecast
Average Price Target
$19.57
▲(33.67% Upside)
Technical Analysis
Best Analysts Covering BLCO
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-1.46%
assigned a buy rating 2 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.46% per trade.
---